Research posted to the bioRxiv* preprint server has shown that procaine and procaine-hydrochloride can reduce replication of SARS-CoV-2 and influenza A viruses in infected cells and reduce the production of cytokines by the viruses, making them potentially useful for treating COVID-19.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mainly infects the bronchial and alveolar epithelial cells. Severe infection can lead to pneumonia, pulmonary edema, and multiple organ failure. In addition, cardiovascular complications and high inflammatory markers have been observed, indicating problems in the regulation of the immune system. Similar to past influenza pandemics, treating severe cases of COVID-19 has proved challenging. Metacam
Although new SARS-CoV-2 vaccines have proven effective in either preventing or reducing the severity of the disease, there are questions about how much protection they can confer with emerging new variants of the virus. Thus, there is a need for effective drugs that can combat the virus. Aside from fighting the actual virus, drugs could target the cellular factors that promote virus growth or inhibit excessive immune responses.
Local anesthetics have anti-inflammatory and anti-oxidative properties. Studies have also reported their antiviral potential and their ability to regulate cellular factors such as G protein-coupled receptors (GPRs) and mitogen-activated protein kinases (MAPK). These factors are used by the virus for their replication.
Procaine is a commonly used local anesthetic. Researchers from Germany investigated whether a procaine-based substance, ProcCluster® (PC) could inhibit SARS-CoV-2 infection. PC has been used in Germany for several years to prepare oral and dermal prescription drugs.
*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.
The researchers studied the effect of procaine and procaine-hydrochloride in SARS-CoV-2-induced cell disturbance, viral mRNA synthesis, and viral replication in Vero-76 or MDCK cells infected with the virus. They also looked at procaine’s effect on the influenza A virus.
They found that procaine could inhibit cell death because of viral infection at millimolar concentrations, indicating decreased viral replication. They next studied how procaine affects the progeny of the viruses in Calu-3 cells after several replication cycles. Amounts of both SARS-CoV-2 and influenza viruses were reduced based on the concentration of procaine.
Using a proliferation assay, the authors found that the use of procaine or procaine-hydrochloride does not affect cellular replication or viability.
The levels of virus spike protein were also reduced in progeny viral titers. Using immunofluorescence assays, the team observed accumulation of spike protein in untreated cells, whereas reduced spike protein levels were seen in procaine-treated cells.
For the influenza-infected cells, they saw an accumulation of the nucleoprotein in the untreated cells, which was reduced when the cells were treated with procaine. Both these observations suggest procaine can inhibit viral infection.
Treatment with procaine also reduced viral mRNA synthesis, found using qRT-PCR analysis. The mRNA synthesis of many cytokines was also decreased in the presence of procaine.
Severe COVID-19 and flu are characterized by increased cytokine levels leading to inflammation and cell death, and the ability of procaine to reduce this points to its use as a potential antiviral.
Thus, the results show the ability of procaine and procaine-hydrochloride to inhibit SARS-CoV-2 and influenza A infection and reduce cytokine levels. More studies can elucidate the cellular mechanisms of how procaine inhibits the viruses.
“Since the active ingredient procaine is well-tolerated and already used in the clinics for anesthetic purposes, the further investigation of this substance could enable its reuse in antiviral therapy, including SARS-CoV-2,” write the authors.
*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.
Posted in: Drug Trial News | Medical Research News | Disease/Infection News | Pharmaceutical News
Tags: Anesthetics, Anti-Inflammatory, Assay, B Cell, Cardiology, Cell, Cell Death, Coronavirus, Coronavirus Disease COVID-19, covid-19, Cytokine, Cytokines, Drugs, Edema, Flu, Immune System, in vitro, Inflammation, Influenza, Microscopy, Pneumonia, Proliferation, Protein, Protein Expression, Protein Synthesis, Pulmonary Edema, Research, Respiratory, SARS, SARS-CoV-2, Severe Acute Respiratory, Severe Acute Respiratory Syndrome, Spike Protein, Syndrome, T-Cell, Virus
Lakshmi Supriya got her BSc in Industrial Chemistry from IIT Kharagpur (India) and a Ph.D. in Polymer Science and Engineering from Virginia Tech (USA).
Please use one of the following formats to cite this article in your essay, paper or report:
Supriya, Lakshmi. (2021, June 10). Local anesthetic procaine inhibits SARS-CoV-2 in vitro. News-Medical. Retrieved on June 05, 2024 from https://www.news-medical.net/news/20210610/Local-anesthetic-procaine-inhibits-SARS-CoV-2-in-vitro.aspx.
Supriya, Lakshmi. "Local anesthetic procaine inhibits SARS-CoV-2 in vitro". News-Medical. 05 June 2024. <https://www.news-medical.net/news/20210610/Local-anesthetic-procaine-inhibits-SARS-CoV-2-in-vitro.aspx>.
Supriya, Lakshmi. "Local anesthetic procaine inhibits SARS-CoV-2 in vitro". News-Medical. https://www.news-medical.net/news/20210610/Local-anesthetic-procaine-inhibits-SARS-CoV-2-in-vitro.aspx. (accessed June 05, 2024).
Supriya, Lakshmi. 2021. Local anesthetic procaine inhibits SARS-CoV-2 in vitro. News-Medical, viewed 05 June 2024, https://www.news-medical.net/news/20210610/Local-anesthetic-procaine-inhibits-SARS-CoV-2-in-vitro.aspx.
In this interview, NewsMedical talks to Santi Dominguez about the genesis of SCiY, and how the consortium intends to empower scientists and researchers.
n this interview, Dr. Michelle Chen, Senior Director of Analytical Sciences at Wyatt Technology, talks to NewsMedical about how to use light scattering techniques to analyze proteins for their multi-attribute quantification (MAQ).
In this interview, NewsMedical talks to Amanda Jones at Revvity about the strategies and solutions available to revolutionize the landscape of R&D in clinical research.
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.
News-Medical.net - An AZoNetwork Site
Owned and operated by AZoNetwork, © 2000-2024
Your AI Powered Scientific Assistant
Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.
A few things you need to know before we start. Please read and accept to continue.
Azthena may occasionally provide inaccurate responses. Read the full terms.
While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.
Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.
Please do not ask questions that use sensitive or confidential information.
Ethyl 3-Oxo-4-Phenylbutanoate Read the full Terms & Conditions.